3 Works cited FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize, accessed February 2, 2026, Semaglutide Shortage Resolved McDermott Will & Schulte, accessed February 2, 2026, GLP-1 Update: Court Backs FDA in Tirzepatide Compounding Case, accessed February 2, 2026, The Return of 503B Compounding of GLP-1 Medications Frier Levitt, accessed February 2, 2026, The Strategic Imperative of Pharmaceutical Competitor Analysis: A Comprehensive Guide for 2026 and Beyond DrugPatentWatch, accessed February 2, 2026, Maximizing ROI on Drug Development by Monitoring Competitive Patent Portfolios, accessed February 2, 2026, Compounded Drug Products That Are Essentially Copies of Approved Drug Products Under Section 503B of the Federal Food, Drug, and Cosmetic Act FDA, accessed February 2, 2026, GLP-1 Weight-Loss Drugs Off Shortage List
Decreased appetite goes beyond normal satiety
If youre prone to nausea, an evening dose might lessen daytime discomfort
Risk of suicidality with GLP-1 drugs
Targets 26 , 507512 (2022)
Some older studies examined combinations of weaker GLP-1 drugs with DPP-4 inhibitors, showing modest additional glucose lowering compared to either drug alone, but the incremental benefit did not justify the added complexity and cost for most patients